Plus Therapeutics recently secured a national coverage agreement with UnitedHealthcare for its CNSide diagnostic kit, opening access to over 50 million U.S. patients.
Reddit discussion in r/pennystocks Wednesday rocketed PSTV to a top-3 ticker ranking by score, with users sharing detailed DD highlighting CNSide's high accuracy and 80-85% profit margins.
Despite strong bullish sentiment (68%), the stock remains a high-risk small-cap biotech burning cash, with Nasdaq compliance and commercial rollout execution still key unknowns.
What Drove the Surge in Discussion?
The primary catalyst cited across nearly every Reddit post was the UnitedHealthcare deal, which effectively gives 50 million-plus insured Americans access to PSTV's cerebrospinal fluid-based test for detecting brain and spinal metastases. Several users highlighted that the diagnostic kit boasts very high accuracy in peer-reviewed studies and that commercial adoption is already underway at more than 120 cancer centers. One Houston lab recently earned federal accreditation, removing a key barrier to broader reimbursement and rollout.
One of the highest-voted posts on r/pennystocks carried the title “$PSTV: Next Big Thong?” and included the author's personal analysis of the company's financial trajectory. The thread noted that PSTV is still burning cash — typical for a development-stage biotech — but that the diagnostic test's 80-85% gross margins could quickly transform the business if hospital adoption scales. Another popular thread, “PSTV quick & honest dd,” recounted how the stock originally appeared on the author's radar via an AI recommendation months earlier at $0.40, before the UnitedHealthcare news pushed it to roughly $0.60.
Sentiment and Engagement
The overall sentiment on r/pennystocks for PSTV stood at an emphatically bullish 0.68 on Wednesday, far above the subreddit's typical neutral-to-slightly-bullish average. The ticker generated 95 posts on the subreddit, 2,297 upvotes, and 1,845 comments — a signal that the UnitedHealthcare catalyst resonated deeply among retail traders looking for the next small-cap breakout.
Sentiment: 68% bullish, 16% bearish, 16% neutral.
While the discussion overwhelmingly leaned positive, many posters were careful to frame their investment as speculative. The author of the “Next Big Thong” post openly described his own position as a small initial bet, and the “quick & honest dd” thread similarly noted the high-risk nature of the stock. A third post, “PSTV, DVLT, ATCH,” presented the ticker alongside other high-risk penny plays, asking the community which one they were “gambling on.” That post attracted 98 upvotes and 93 comments, confirming that PSTV is squarely in the high-risk, high-reward bucket for the r/pennystocks crowd.
Upcoming Catalysts and Risks
Reddit contributors also looked ahead to the rest of the year and 2026. One detailed thread titled “PSTV Upcoming Catalysts” outlined the commercial launch of CNSide — which began in Texas in mid-2025 and is set to expand to other states — along with clinical trial updates for the company's radiotherapy candidate, REYOBIQ, and several upcoming conference presentations. The author stressed that the fundamentals are improving, but the company remains in its early revenue stage and must execute on its rollout plan.
On the risk side, Nasdaq compliance remains a persistent concern. Several commenters noted that PSTV's share price, while up from its lows, still hovers in penny-stock territory. The company's ongoing cash burn means that future dilution or additional financing rounds could weigh on the stock if commercial revenue doesn't ramp quickly enough.
No same-day news articles were available for
What to Watch
For traders following
Subscribe to Tendie.bot for more market recaps.